
|Videos|April 29, 2019
JAK Inhibition for the Management of Primary Myelofibrosis
JAK Inhibition for the Management of Primary Myelofibrosis
Advertisement
Case: 66-Year-Old Man Diagnosed With Primary Myelofibrosis
January 2019
- A 66-year old man presents to primary care physician with complaints of fatigue, headache, and abdominal discomfort when taking deep breaths
- PMH: depression
- PE: Splenomegaly ~7 cm below left costal margin
- Lab values:
- HGB: 9.2 g/dL
- Platelets: 242 x 109/L
- WBC: 26.2 x 109/L
- Serum LDH: 1400 U/L
- Serum EPO: 10.9 mU/mL
- Bone Marrow Biopsy:
- MF-3
- Circulating blasts, 1.1%
- JAK V617Fmutation; trisomy 8
- Peripheral Blood Smear: leukoerythroblastosis
- Diagnosis: Primary myelofibrosis
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















